175205-45-5 Usage
General Description
1-(2-Chlorobenzyl)-5-oxopyrrolidine-3-carboxylic acid is a chemical compound with a molecular formula C13H13NO4Cl. It is primarily used in the synthesis of pharmaceutical drugs and research chemicals. 1-(2-CHLOROBENZYL)-5-OXOPYRROLIDINE-3-CARBOXYLIC ACID is a derivative of pyrrolidin-3-one and contains a carboxylic acid group and a chlorobenzyl group. It can be used as a building block for the synthesis of various bioactive compounds and has potential applications in the field of medicinal chemistry. Additionally, it may have antibacterial and antifungal properties, although further research is needed to confirm its potential therapeutic uses.
Check Digit Verification of cas no
The CAS Registry Mumber 175205-45-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,5,2,0 and 5 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 175205-45:
(8*1)+(7*7)+(6*5)+(5*2)+(4*0)+(3*5)+(2*4)+(1*5)=125
125 % 10 = 5
So 175205-45-5 is a valid CAS Registry Number.
InChI:InChI=1/C12H12ClNO3/c13-10-4-2-1-3-8(10)6-14-7-9(12(16)17)5-11(14)15/h1-4,9H,5-7H2,(H,16,17)
175205-45-5Relevant articles and documents
CCR5 antagonists as anti-HIV-1 agents. 1. Synthesis and biological evaluation of 5-oxopyrrolidine-3-carboxamide derivatives
Imamura, Shinichi,Ishihara, Yuji,Hattori, Taeko,Kurasawa, Osamu,Matsushita, Yoshihiro,Sugihara, Yoshihiro,Kanzaki, Naoyuki,Iizawa, Yuji,Baba, Masanori,Hashiguchi, Shohei
, p. 63 - 73 (2007/10/03)
A novel lead compound, N-{3-[4-(4-fluorobenzoyl)piperidin-1-yl]propyl}-1- methyl-5-oxo-N-phenylpyrrolidine-3-carboxamide (1), was identified as a CCR5 antagonist by high-throughput screening using [125I]RANTES and CCR5-expressing CHO cells. The IC50 value of 1 was 1.9 μM. In an effort to improve the binding affinity of 1, a series of 5-oxopyrrolidine-3- carboxamides was synthesized. Introduction of 3,4-dichloro substituents to the central phenyl ring (10i, IC50=0.057 μM; 11b, IC 50=0.050 μM) or replacing the 1-methyl group of the 5-oxopyrrolidine moiety with a 1-benzyl group (12e, IC50=0.038 μM) was found to be effective for improving CCR5 affinity. Compound 10i, 11b, and 12e also inhibited CCR5-using HIV-1 envelope-mediated membrane fusion with IC50 values of 0.44, 0.19, and 0.49 μM, respectively.